Abstract
The CRASH-2 and CRASH-3 trials evaluated the use of tranexamic acid (TXA) in trauma patients, assessing the outcomes of mortality reduction as well as thromboembolic outcomes. Neither study included any significant number of US trauma patients. The discussed manuscript is a retrospective study of adult trauma patients, in the US, who received TXA and assess overall mortality and thromboembolic outcomes. We review the manuscript as well as the Hot-Off-the-Press podcast and social media commentary.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Academic emergency medicine : official journal of the Society for Academic Emergency Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
